



New York State Medicaid Drug Utilization Review (DUR) Board Meeting
The DUR Board will meet on May 12, 2022, from 9:00 a.m. to 4:00 p.m.
Meeting Room 2, Concourse Level, Empire State Plaza, Albany NY

This meeting will be available for public viewing from Meeting Room 2, Concourse Level, Empire State Plaza, Albany NY and by a real-time webcast.

The link to the webcast is available from the Department of Health Events/Webcasts webpage:
<https://www.health.ny.gov/events/webcasts/>

Agenda Items

A. Preferred Drug Program (PDP) Review

The DUR Board will review the therapeutic classes, as they pertain to the PDP (NYS Public Health Law, Sections 272 and 273

<https://www.nysenate.gov/legislation/laws/PBH/A2-AT1>

- The DUR Board will review the therapeutic classes listed below to recommend preferred and non-preferred drugs. The review may also include relevant clinical criteria updates applicable to a therapeutic class.
- For therapeutic classes currently subject to the PDP, the DUR Board will only consider clinical information, which is new since the previous review of the therapeutic class and then consider financial information.
- New clinical information may include new drug or drug product information, new indications, new safety information, or newly published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data is poor quality evidence for the purpose of PDP reviews and submission is discouraged.
- The Preferred Drug List (PDL) which includes the current preferred and non-preferred status within each therapeutic class may be viewed at:
https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

1. Cholesterol Absorption Inhibitors
(Previous review date: 06/15/2012)
2. Antimigraine Agents – Other
(Previous review date: 05/13/2021)
3. Movement Disorder Agents
(Previous review date: 05/16/2019)

4. Acne Agents – Topical
(Previous review date: 07/23/2020)
5. Anti-Fungals - Topical
(Previous review date: 04/27/2017)
6. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
(Previous review date: 04/26/2018)
7. Glucagon-like Peptide-1 (GLP-1) Agonists
(Previous review date: 07/23/2020)
8. Growth Hormones
(Previous review date: 05/16/2019)
9. Antihyperuricemics
(Previous review date: 05/13/2021)
10. Anticholinergics/COPD Agents
(Previous review date: 07/15/2021)

B. Drug Utilization Review (DUR)

The DUR Board will review the following drug(s) and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate drug utilization:

1. Spravato (esketamine)

C. Pharmacy Program Updates

The DUR Board will be provided updates on the following topic(s):

1. Asthma Guidelines: Use of inhaled corticosteroids / long-acting beta agonist combinations for maintenance and reliever therapy.

Agenda Timeline (subject to change based on meeting proceedings)

9:00 – 9:15	Welcome and Opening Comments
9:15 – 10:45	Public Comment Period
10:45 – 12:00	PDP (Clinical Reviews/Criteria Updates)
12:00 – 1:30	Executive Session (PDP Financial Reviews) / Midday Break
1:30 – 2:00	PDP Recommendations
2:00 – 2:45	Drug Utilization Review
2:45 – 3:30	Pharmacy Program Updates
3:30 – 4:00	Final Comments and Adjournment

Interested parties must submit a request to provide public comment during the DUR Board meeting and must complete the registration process by May 4, 2022. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov (please reference DUR Board Meeting Speaker Request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes) and the total comment period will not exceed ninety (90) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment to meet agenda timelines and accomplish meeting objectives.

All written statements must be received in an electronic format by May 4, 2022. Written statements should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included.

Clinical information must be submitted in an electronic format by April 30, 2022, or the DUR Board may not have ample time to review the information.

All information must be sent to the DOH. Interested parties should not contact or send any information directly to DUR Board members.